| Actemra SC (tocilizumab SC) / Roche, Halozyme |
NCT01194414 / 2010-018375-22: A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis |
|
|
| Completed | 3 | 1262 | US, Canada, Europe, RoW | tocilizumab SC, RoActemra/Actemra, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs) | Hoffmann-La Roche | Rheumatoid Arthritis | 01/12 | 08/13 | | |
|
|
|
|
|
|
|
|
|
|
BREVACTA, NCT01232569 / 2010-019912-18: A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis |
|
|
| Completed | 3 | 656 | US, Canada, Europe, RoW | Tocilizumab 162 mg, RoActemra, Actemra, Placebo | Hoffmann-La Roche | Rheumatoid Arthritis | 05/12 | 11/13 | | |
|
|
|
|
|
|
NCT01662063: A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA) |
|
|
| Completed | 3 | 218 | US | Tocilizumab, RoActemra/Actemra | Genentech, Inc. | Rheumatoid Arthritis | 04/14 | 06/14 | | |
NCT01772316 / 2012-002632-87: A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | 3 | 47 | Europe | tocilizumab, Roactemra | Hoffmann-La Roche | Rheumatoid Arthritis | 05/15 | 05/15 | | |
NCT01995201 / 2013-002429-52: A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis |
|
|
| Completed | 3 | 401 | Europe | DMARD, methotrexate, tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 07/15 | 03/16 | | |
NCT01988012: A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis. |
|
|
| Completed | 3 | 100 | RoW | tocilizumab, RoActemra/Actemra | Hoffmann-La Roche | Rheumatoid Arthritis | 07/15 | 07/15 | | |
NCT01951170: An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis |
|
|
| Completed | 3 | 52 | RoW | Tocilizumab, RoActemra®/Actemra® | Hoffmann-La Roche | Rheumatoid Arthritis | 08/15 | 08/15 | | |
|
NCT01734993: A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA). |
|
|
| Completed | 3 | 11 | Europe | Tocilizumab, RoActemra, Actemra | Hoffmann-La Roche | Rheumatoid Arthritis | 09/15 | 09/15 | | |
| Completed | 3 | 57 | Europe | tocilizumab, RoActemra/Actemra | Hoffmann-La Roche | Rheumatoid Arthritis | 09/15 | 09/15 | | |
NCT01941940 / 2013-001569-17: A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants |
|
|
| Completed | 3 | 227 | Europe | Tocilizumab, RoActemra, DMARDs | Hoffmann-La Roche | Rheumatoid Arthritis | 09/15 | 07/16 | | |
NCT02001987: A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy |
|
|
| Completed | 3 | 139 | Europe | Tocilizumab, RoActemra, RO4877533, Methotrexate, csDMARDs | Hoffmann-La Roche | Rheumatoid Arthritis | 12/15 | 12/15 | | |
OSCAR, NCT01987479 / 2013-000342-19: A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis |
|
|
| Completed | 3 | 150 | Europe | Non-Biologic DMARDs, Tocilizumab, RoActemra, Actemra, Methotrexate | Hoffmann-La Roche | Rheumatoid Arthritis | 05/16 | 05/16 | | |
NCT01941095 / 2013-000359-42: A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis |
|
|
| Completed | 3 | 100 | Europe | Azathioprine, Chloroquine, Hydroxychloroquine, Leflunomide, Methotrexate, Sulfasalazine, Tocilizumab, RoActemra, Actemra | Hoffmann-La Roche | Rheumatoid Arthritis | 07/16 | 07/16 | | |
ACT-MOVE, NCT02046603 / 2013-000054-22: A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent |
|
|
| Completed | 3 | 162 | Europe | Tocilizumab, RoActemra, Actemra, DMARDs, Oral Corticosteroids, Methotrexate | Hoffmann-La Roche | Rheumatoid Arthritis | 08/16 | 08/16 | | |
NCT02046616 / 2013-002007-34: A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs) |
|
|
| Completed | 3 | 133 | Europe | Tocilizumab, RoActemra, Actemra, Methotrexate, Non-Biologic DMARDs | Hoffmann-La Roche | Rheumatoid Arthritis | 09/16 | 09/16 | | |
NCT02011334: A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs. |
|
|
| Completed | 3 | 285 | RoW | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 10/16 | 10/16 | | |
COMP-ACT, NCT01855789: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX |
|
|
| Completed | 3 | 718 | US | Tocilizumab (TCZ), Actemra, Methotrexate (MTX), Placebo (PBO) | Hoffmann-La Roche | Rheumatoid Arthritis | 10/16 | 10/16 | | |
